Arterial Hypertension and Haematopoietic stem-cell transplantation (HSCT): what the trial registry contains
The ClinicalTrials.gov registry holds 5 records for HSCT in Arterial Hypertension: 2 recruiting now, 1 labelled Phase 3 or 4, across 2 countries. Snapshot 2026-08-29.
Why this is studied in Arterial Hypertension
Resistant hypertension is a plumbing-and-signalling problem: vascular stiffness, renal sodium handling and sympathetic tone. Cell approaches are studied mostly for endothelial repair and inflammation, usually as an add-on to drugs rather than a replacement. Blood pressure is also the most placebo-responsive vital sign in medicine, which shapes how these trials must be designed.
What HSCT means in this table
Haematopoietic transplantation is the oldest and most consequential cell therapy in medicine, with conditioning regimens that carry real mortality risk alongside genuine disease-modifying power. Registrations under this label therefore mix decades-old standard-of-care protocols with newer autoimmune-reset trials, and the risk profile is nothing like that of an outpatient infusion.
The numbers
Every figure below comes from one reproducible query (hypertension x hematopoietic stem cell transplantation) run against ClinicalTrials.gov API v2 on 2026-08-29.
| Metric | Value |
|---|---|
| Registered studies (all statuses) | 5 |
| Interventional studies in the sample | 4 |
| Recruiting right now | 2 |
| Completed | 2 |
| Terminated, withdrawn or suspended | 0 |
| Phase 3 or Phase 4 records | 1 |
| Countries with at least one site | 2 |
| Median planned enrolment | 20 participants |
| Largest single planned enrolment | 400 participants |
| First / most recent start year | 2014 — 2026 |
How mature is this evidence?
The ladder is partly climbed: 1 confirmatory-phase records against 5 in total, with the remainder concentrated in dose-finding and safety territory.
2 records are marked completed and 0 ended early (terminated, withdrawn or suspended): 0% of registrations did not run to plan.
| Phase label | Records | Share |
|---|---|---|
| Not applicable | 2 | 40% |
| Phase 3 | 1 | 20% |
| Phase 1 | 1 | 20% |
| Phase 2 | 1 | 20% |
Median planned enrolment is 20 participants (largest single study: 400). Trials of this size can describe safety and generate hypotheses; detecting a modest clinical benefit reliably usually needs substantially larger numbers with a control group.
Where the studies are
Across 2 countries with registered sites, United States dominates at roughly 75% — a concentration driven by funding and regulation rather than by clinical outcome.
| Country | Studies with a site there |
|---|---|
| United States | 3 |
| Brazil | 1 |
Legal pathway differs by country — see where cell therapy is legal, by country.
Who runs them
The sponsor mix is academic (4 academic or hospital, 1 commercial among the most frequent lead sponsors).
- National Heart, Lung, and Blood Institute (NHLBI) — 1 record
- City of Hope Medical Center — 1 record
- University of Sao Paulo — 1 record
- Paul Szabolcs — 1 record
- Assistance Publique - Hôpitaux de Paris — 1 record
Representative registered studies
Recruiting studies first, then the most advanced phases. Each identifier links to the registry record, where eligibility criteria, outcome measures and contacts are published.
| Study | Phase | Status | Planned n | Lead sponsor | Start |
|---|---|---|---|---|---|
| NCT07613099 — Fibrotic Disease Activity in Cardiopulmonary Disorders Using 18F-Fibroblast Activation Protein Inhibitor (18F-FAPI-74) PET/CT Imaging | Phase 3 | Recruiting | 210 | National Heart, Lung, and Blood Institute (NHLBI) | 2026-09-02 |
| NCT03630211 — Autologous Stem Cell Transplantation in Patients With Systemic Sclerosis | Phase 2 | Recruiting | 8 | Paul Szabolcs | 2018-07-31 |
| NCT02330978 — Intravitreal Mesenchymal Stem Cell Transplantation in Advanced Glaucoma. | Phase 1 | Completed | 2 | University of Sao Paulo | 2014-01 |
| NCT07157670 — Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. | n/a | Not Yet Recruiting | 400 | Assistance Publique - Hôpitaux de Paris | 2025-09-15 |
| NCT02077218 — Computed Tomography and Biomarker Analysis in Diagnosing Coronary Artery Disease in Asymptomatic Patients Who Have Undergone Stem Cell Transplant | n/a | Completed | 20 | City of Hope Medical Center | 2014-02 |
What this page does and does not tell you
A registry is a plan repository. Counting entries tells you what people intended to study, which is a weaker thing than what they found.
If a clinic offers you this today, the useful question is not "is there research?" but "which of these registered studies is mine part of, and if none, what evidence applies to the exact product I am being sold?" The Provider Question Builder turns that into a scored checklist.
Frequently asked
How many HSCT studies for Arterial Hypertension are recruiting right now?
2 of 5 registered records were listed as recruiting in the 2026-08-29 snapshot. Recruitment status changes frequently; the registry record is authoritative.
Is HSCT an approved treatment for Arterial Hypertension?
Registration on ClinicalTrials.gov is not approval. Approval is granted by a regulator for a specific product and indication after review of submitted evidence. 5 registered studies tell you research exists, not that a product cleared review.
How advanced is the research on HSCT for Arterial Hypertension?
1 of 5 records carry a Phase 3 or Phase 4 label and 2 are marked completed. Registrations run from 2014 to 2026.
Registry and literature counts retrieved 2026-08-29 (ClinicalTrials.gov API v2; PubMed E-utilities). Registration or publication volume measures research activity, not effectiveness or approval. Educational information — not medical advice; verify product, indication, legal pathway and evidence with an independent qualified physician. Page generated 2026-08-29. See our editorial standards.
More on this condition
- Arterial Hypertension: cell-therapy evidence and registered trials
- How much does stem cell therapy for Arterial Hypertension cost? (2026)
- Arterial Hypertension stem cell therapy — your questions answered (2026)
- Arterial Hypertension: cell-therapy evidence by therapy class
- MSC vs exosomes for Arterial Hypertension: what the registries show
Download the query data
Query totals are full API matches; status, phase and country counts describe the first up to 400 returned records per query. Query classes overlap and must not be summed as unique trials. Counts are not treatment outcomes. Snapshot: 2026-08-29. Methods and field definitions.